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Dear Editor,
Holmes tremor (HT) is a low-frequency rest and intentional
tremor frequently affecting the upper limb. The tremor,
typically aggravated by movements, may in addition show
an intrinsic postural component. It develops weeks to
months after the onset of focal lesions of the brainstem,
cerebellum and thalamus [1]. The response to a number of
pharmacological agents consistently employed in the
clinical practice, including levodopa, dopamine agonists,
levetiracetam, clonazepam, zonisamide and propranolol, is
rather unsatisfactory [2]. In drug-refractory cases, thalam-
otomy or deep brain stimulation of the nucleus ventralis
intermedius of the thalamus may prove useful, but neuro-
surgical approaches, although potentially beneficial, are
limited or avoided for being invasive and expensive [2].
Herewith, we report on a subject suffering for HT
secondary to thalamic hemorrhage. The patient showed a
good response to treatment with botulinum toxin type A
(BoNT-A).
A 45-year-old, right-handed man with a history of
hypertension developed right hemiparesis (manual muscle
testing—MMT—score 2/5 in the right arm and leg),
superficial hemihypoesthesia and dysarthria due to a left
thalamic hemorrhage that was diagnosed by brain MRI.
Following the acute phase, the patient was transferred to a
rehabilitation unit, where he showed a progressive
improvement. One month later, muscle strength of the right
limbs recovered to MMT score 4/5. Two months after
stroke the almost complete recovery of the hemiparesis was
counterbalanced by the onset of postural, kinetic and
resting tremor of the right arm. The tremor was irregular, of
large amplitude and slow frequency (3–4 Hz), mostly
proximal (involving the deltoid, biceps and triceps brachii),
and accompanied by slight athetoid movements of the right
hand (video as supplementary material). The tremor
interfered significantly with activities of daily living [TRG
Essential Tremor Rating Assessment Scale (TETRAS)
‘‘Activities of daily living subscale’’ score = 32; ‘‘Perfor-
mance subscale’’ score = 13]. A further MRI scan showed
the expected evolution of the thalamic hemorrhage and no
additional focal vascular lesions. The patient was diag-
nosed presenting HT and treated with levodopa (100 mg,
t.i.d., for 1 month), clonazepam (1 mg, t.i.d., for another
month), and propranolol (40 mg, b.i.d., for a further
month). The treatment had no benefit (see video, pre-
therapy session). He refused dopamine agonists and
levetiracetam.
On the basis of previous studies reporting the effec-
tiveness of BoNT-A for treatment of upper limb tremor [3],
we planned to treat the patient with BoNT-A. Following
approval by our local Ethics Committee, we initiated the
treatment by performing local injections of BoNT-A
(abobotulinumtoxinA) into the following muscles of the
right arm: deltoid and triceps brachii (250 IU each) and
biceps brachii (500 IU). Tremulous muscle activity was
identified by muscle palpation and confirmed by elec-
tromyography. Treatment was performed without
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ultrasonography guide. BoNT-A injections were repeated
at 3-month interval for a total of three sessions for a total
follow-up period of 9 months. After the second session, the
patient showed a significant reduction of tremor severity, in
particular of resting and postural components, with marked
improvement of daily activities such as feeding, drinking,
dressing and writing (TETRAS ‘‘Activities of daily living
subscale’’ score = 20; ‘‘Performance subscale’’ score = 8)
(video in supplementary material). The efficacy of both
second and third injections of BoNT-A lasted more than
2 months. BoNT-A injections were not accompanied either
by muscle weakness, as measured by MMT score, or by
other significant side effect.
HT is a relatively rare condition caused by focal lesions
in the brainstem, cerebellum or thalamus, causing dys-
function of the basal ganglia and cerebellofugal pathways
[1, 4], thus concurring with the onset of resting, postural
and kinetic tremor. In most cases, pharmacological therapy
does not achieve satisfactory results [2]. The effectiveness
of BoNT-A for treatment of upper limb tremor has been
reported recently, with functional benefit in more than
60 % of cases [3]. Moreover, BoNT-A has been recom-
mended for treatment of refractory essential tremor of the
upper limbs based on the results of class II studies [3]. Ahn
et al. [5] reported recently the efficacy of BoNT-A injec-
tion in a case with HT secondary to pontine hemorrhage.
Consistent with the previous report [5], our patient expe-
rienced a satisfactory improvement of resting and postural
tremor together with attenuation of intentional tremor.
Moreover, the present report suggests that infiltration of
proximal muscles improves motor performances even at
distal level. Such an extended efficacy should be taken into
account when there is concern for the occurrence of muscle
weakness frequently complicating BoNT-A infiltration of
the forearm muscles and/or intrinsic muscles of the hand.
In conclusion, this case suggests that BoNT-A is
effective for treatment of HT. If the efficacy and safety of
BoNT-A will be confirmed by further studies on larger
series, BoNT-A might well be considered as therapeutic
option for the HT unresponsive to oral drugs.
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